50th week of 2015 patent applcation highlights part 23 |
Patent application number | Title | Published |
20150353518 | CATALYST AND CATALYTIC PROCESS FOR THE ETHERIFICATION/REDUCTION OF FURFURYL DERIVATIVES TO TETRAHYDROFURFURYL ETHERS - The invention relates to a method for producing tetrahydrofurfuryl ethers, characterised in that it involves carrying out consecutive etherification/reduction reactions based on a compound containing at least one furan ring, in the presence of at least one alcohol and at least one catalyst, optionally in the presence of H | 2015-12-10 |
20150353519 | THERAPEUTIC AGENT FOR DISEASE BASED ON INHIBITORY EFFECT OF MACROPHAGE MIGRATION INHIBITORY FACTOR - A benzopyran derivative represented by general formula [1], or a salt thereof, is useful in therapeutic or preventive treatment of disease, wherein said therapeutic or preventive treatment is effective because said benzopyran derivative, or salt thereof, binds to MIF, has an MIF inhibitory effect, and inhibits MIF. | 2015-12-10 |
20150353520 | SALTS AND CRYSTAL FORMS - This invention relates to salts and crystal forms of (S)-6-chloro-7-(1,1-dimethylethyl)-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid, Compound A, which is cyclooxygenase-2 inhibitor. The present invention provides a salt of compound A, a crystal form thereof, a process for preparing the said salt and a pharmaceutical composition thereof and its use. The salts and/or co-crystals of Compound A of the present invention show good formulation properties such as high aqueous solubility, good intrinsic dissolution, good crystallinity, good thermal stability or low hygroscopicity. | 2015-12-10 |
20150353521 | 2-OXO-1,3-DIOXOLANE-4-CARBOXAMIDE BUILDING BLOCKS, THEIR PREPARATION AND USE - The present invention suggests a 2-oxo-1,3-dioxolane-4-carboxamide of formula (I), | 2015-12-10 |
20150353522 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MODERATE TO SEVERE PAIN - The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I; and methods for treating or preventing moderate to severe pain, may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of muscle pain, spasticity, neuropathic pain, fibromyalgia, post-operative pain, muscle spasticity, headache, chronic pain, sub-chronic pain and local pain. | 2015-12-10 |
20150353523 | N-Thio-anthranilamid compounds and their use as pesticides - N-Thio-anthranilamid compounds of formula (I) | 2015-12-10 |
20150353524 | PYRIDINE COMPOUNDS USED AS PI3 KINASE INHIBITORS - The present invention is directed to novel pyridines, their derivatives, pharmaceutically acceptable salts, solvates and hydrates thereof. The present invention discloses compounds of Formulas I and II. The compounds and compositions of the present invention have protein kinases inhibitory activities and are expected to be useful for the treatment of protein kinases mediated diseases and conditions. | 2015-12-10 |
20150353525 | ANHYDROUS LENALIDOMIDE FORM-I - Anhydrous polymorphic form-I of anti cancer drug, Lenalidomide whose chemical name is 3-(4-amino-1-oxo-1,3-dihydro-isoindole-2-yl)-piperidine-2,6-dione, is disclosed. Alternate methods for making anhydrous polymorphic form-I of Lenalidomide are also disclosed. | 2015-12-10 |
20150353526 | TETRAHYDROPHENANTHRIDINONES AND TETRAHYDROCYCLOPENTAQUINOLINONES AS PARP AND TUBULIN POLYMERIZATION INHIBITORS - The present invention provides compounds of formula (I), their use as inhibitors of tubulin polymerization and their use as PARP inhibitors as well as pharmaceutical compositions comprising said compounds of formula (I) | 2015-12-10 |
20150353527 | NON-SELECTIVE KINASE INHIBITORS - Disclosed herein are compounds, compositions, and methods for preventing and treating proliferative diseases associated with aberrant receptor tyrosine kinase (RTK) activity. The therapeutic indications described herein more specifically relate to the non-selective inhibition of RTKs associated with vascular and pulmonary disorders. | 2015-12-10 |
20150353528 | OPTICALLY ACTIVE PYRAZOLYLAMINOQUINAZOLINE, AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF - Provided herein is an optically active pyrozolylaminoquinazaline, and pharmaceutical compositions thereof. Also provided herein is a method for treating, preventing, or ameliorating one or more symptoms of a JAK-mediated condition, disorder, or disease. Further provided herein is a method for treating, preventing, or ameliorating one or more symptoms of a proliferative disease, inflammatory disease, or renal disease. | 2015-12-10 |
20150353529 | ANTIVIRAL COMPOUNDS - The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds. | 2015-12-10 |
20150353530 | NOVEL FUNCTIONALIZED 4-(PHENOXYMETHYL(-1,3-DIOXOLANE ANALOGS EXHIBITING CYTOCHROME P450 INHIBITION AND THEIR METHOD OF USE - Embodiments of the present invention relate to 4-(phenoxymethyl)-1,3-dioxolane analogs and pharmaceutical compositions thereof having a disease-modifying action in the treatment of diseases associated with the overproduction of cortisol that include metabolic syndrome, and any involving the overproduction of cortisol. | 2015-12-10 |
20150353531 | CRYSTALLINE N--5-CHLORO-4-(4-CHLORO-1-METHYL-1H-PYRAZOL-5-YL)-2-THIOPHENECARBOXAMIDE HYDROCHLORIDE - An improved AKT inhibiting compound, crystalline N-{(1S)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride. | 2015-12-10 |
20150353532 | PYRAZOLINE DERIVATIVES AS INSECTICIDAL COMPOUNDS - The present invention relates to compounds of formula (I) wherein P is selected from P1 and P2, or P and R | 2015-12-10 |
20150353533 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS - Disclosed are compounds having the formula: | 2015-12-10 |
20150353534 | THIAZOLE DERIVATIVES AS INHIBITORS OF BRUTON'S TYROSINE KINASE - This application discloses compounds according to generic Formula I: wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient. | 2015-12-10 |
20150353535 | THIAZOLE-SUBSTITUTED AMINOPYRIDINES AS SPLEEN TYROSINE KINASE INHIBITORS - The invention provides certain thiazole-substituted aminopyridine compounds of the Formula (I) (I) or pharmaceutically acceptable salts thereof, wherein R | 2015-12-10 |
20150353536 | Complex targeting hepatitis B virus - A compound medicine for treating acute and chronic hepatitis B, includes a polyphenolic selenium compound having a functional group of alkali metal ion and selenium coordination complex, which has functions of directly killing HBV and destroying replication template of HBV. Auxiliary formulas thereof include high-purity oxymatrine and glycyrrhizin sulfate. The oxymatrine has an effect of anti-HBV, and is capable of treating acute and chronic hepatitis B, regulating immune system and increasing leukocyte. Serving as a main hepatocyte membrane protective agent, the glycyrrhizin sulfate has not only an effect of anti-inflammation, but also it is capable of regulating immune system and protecting hepatocyte. The compound medicine has no toxicity or side effect. | 2015-12-10 |
20150353537 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY - The invention relates to new bicyclic heterocycle compounds, to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer. | 2015-12-10 |
20150353538 | COMPOUNDS AND THERAPEUTIC USES THEREOF - The invention relates to compounds, pharmaceutical compositions and methods useful for treating cancer, systemic or chronic inflammation, rheumatoid arthritis, diabetes, obesity, T-cell mediated autoimmune disease, ischemia, and other complications associated with these diseases and disorders. | 2015-12-10 |
20150353539 | AZAINDOLE DERIVATIVES AS MULTI KINASE INHIBITORS - The present invention relates to compounds of the following formula (I) and/or the pharmaceutically acceptable addition salts, solvates, enantiomers, diastereoisomers thereof, as well as mixtures thereof. The subject matter of the present invention thus also includes the preparation of compounds of formula (I), their uses, in particular in the inhibition of protein kinases which are implicated for example in numerous diseases such as cancers or immune system disorders. | 2015-12-10 |
20150353540 | AZAINDOLE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES - The present invention relates to compounds of the following formula (I) and/or the pharmaceutically acceptable addition salts, solvates, enantiomers, diastereoisomers thereof, as well as mixtures thereof. The subject matter of the present invention thus also includes the preparation of compounds of formula (I), their uses, in particular in the inhibition of protein kinases which are implicated for example in numerous diseases such as cancers or immune system disorders. | 2015-12-10 |
20150353541 | Novel intermediate and polymorphs of 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetra hydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide and process thereof - The present invention provides a novel intermediate as well as novel polymorphs of 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide compound represented by the following structural formula-1 and processes for their preparation. | 2015-12-10 |
20150353542 | METHODS OF USING CELL-CYCLE INHIBITORS TO MODULATE ONE OR MORE PROPERTIES OF A CELL CULTURE - Methods of modulating the properties of a cell culture expressing a protein of interest are provided. In various embodiments the methods relate to the addition of cell cycle inhibitors to growing cell cultures. | 2015-12-10 |
20150353543 | PROCESS FOR THE PREPARATION AND PURIFICATION OF APIXABAN - The present invention provides a process for the preparation and purification of apixaban. | 2015-12-10 |
20150353544 | NOVEL SUBSTITUTED PYRIDO-PIPERAZINONE DERIVATIVES AS GAMMA SECRETASE MODULATORS - The present invention is concerned with novel substituted pyrido-piperazinone derivatives of Formula (I) | 2015-12-10 |
20150353545 | QUORUM SENSING INHIBITORS - The invention relates to compounds for use as quorum sensing inhibitors, and in particular, to quorum sensing inhibitors of | 2015-12-10 |
20150353546 | METALLOENZYME INHIBITOR COMPOUNDS - The instant invention describes compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes. | 2015-12-10 |
20150353547 | Antibacterial Oxadiazolone Derivatives - The invention relates to antibacterial compounds of formula I | 2015-12-10 |
20150353548 | 2-AMINOPYRIDINE COMPOUNDS - The invention provides novel substituted 2-aminopyridine compounds according to Formula (I), their manufacture and use for the treatment of hyperproliferative diseases such as cancer, inflammatory or degenerative diseases. | 2015-12-10 |
20150353549 | Inhibitors Of Histone Deacetylase - This invention comprises the novel compounds of formula (I) | 2015-12-10 |
20150353550 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF - The present application relates to indole and indoline derivatives of formula (I), (II), (III), (IV), (V), or (VI) | 2015-12-10 |
20150353551 | SUBSTITUTED PURINONE COMPOUNDS - The invention relates to compounds of formula (I): (I) as described herein, pharmaceutical preparations comprising such compounds, uses and methods of use for such compounds in the treatment of a disorder or a disease mediated by the activity of as MDM2 and/or MDM4, and combinations comprising such compounds. | 2015-12-10 |
20150353552 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA - The instant invention provides compounds of formula I which are PI3K-delta inhibitors, and as such are useful for the treatment of PI3K-delta-mediated diseases such as inflammation, asthma, COPD and cancer. | 2015-12-10 |
20150353553 | 2,6,7,8 SUBSTITUTED PURINES AS HDM2 INHIBITORS - The present invention provides 2,6,7,8 Substituted Purines as described herein or a pharmaceutically acceptable salt thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same. | 2015-12-10 |
20150353554 | PROCESS FOR PREPARING MEROPENEM TRIHYDRATE - Provided is a process for the preparation of meropenem trihydrate in high purity and high yield, including using a dry methanol solvate of meropenem, which can remarkably reduce the amount of residual solvents in the resulting product, thereby obtain meropenem trihydrate in high purity. | 2015-12-10 |
20150353555 | PROCESS FOR THE SYNTHESIS OF E1 ACTIVATING ENZYME INHIBITORS - The present invention provides processes and synthetic intermediates for the synthesis of 4-substituted ((1S,2S,4R)-2-hydroxy-4-{7H-pyrrolo[2,3-d]pyrimidin-7-yl}cyclopentyl)methyl sulfamates, which are E1 activating enzyme inhibitors, and are useful for the treatment of disorders of cell proliferation, particularly cancer, and other disorders associated with E1 activity. | 2015-12-10 |
20150353556 | ORGANIC COMPOUNDS - Optionally substituted (5- or 7-amino)-3,4-dihydro-(optionally 4-oxo, 4-thioxo or 4-imino)-1H-pyrrolo[3,4-d]pyrimidin-2(6H)-ones, Compounds of Formula (I), processes for their production, their use as pharmaceuticals and pharmaceutical compositions comprising them. | 2015-12-10 |
20150353557 | TYROSINE KINASE INHIBITORS - The present disclosure provides compounds and pharmaceutically acceptable salts thereof that are tyrosine kinase inhibitors, in particular BLK, BMX, EGFR, HER2, HER4, ITK, TEC, BTK, and TXK and are therefore useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer and inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and pharmaceutically acceptable salts thereof and processes for preparing such compounds and pharmaceutically acceptable salts thereof. | 2015-12-10 |
20150353558 | Ionic Liquid, Lubricating Agent, and Magnetic Recording Medium - A lubricating agent including an ionic liquid formed from a Bronsted acid (HX) and a Bronsted base (B), wherein the Bronsted base has a linear hydrocarbon group having 10 or more carbon atoms and the difference between the pKa value of the Bronsted acid in water and the pKa value of the Bronsted base in water is 12 or more. | 2015-12-10 |
20150353559 | NEW BICYCLIC DERIVATIVES - The invention provides novel compounds having the general formula (I) | 2015-12-10 |
20150353560 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE - The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and solid forms of the compounds of this invention. | 2015-12-10 |
20150353561 | NOVEL COMPOUNDS - Compounds of formula (I), described herein, exhibit human neutrophil elastase inhibitory properties, and are useful for the treatment of diseases and conditions in which HNE is implicated. | 2015-12-10 |
20150353562 | TYROSINE KINASE INHIBITORS - The present disclosure provides compounds and pharmaceutically acceptable salts thereof that are tyrosine kinase inhibitors, in particular BLK, BMX, EGFR, HER2, HER4, ITK, TEC, BTK, and TXK and are therefore useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer and inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and pharmaceutically acceptable salts thereof and processes for preparing such compounds and pharmaceutically acceptable salts thereof. | 2015-12-10 |
20150353563 | PYRAZOLO[3,4-D]PYRIMIDINONE COMPOUNDS AS INHIBITORS OF THE P53/MDM2 INTERACTION - The invention relates to compounds of formula (I): as described herein, pharmaceutical preparations comprising such compounds, uses and methods of use for such compounds in the treatment of a disorder or a disease mediated by the activity of MDM2 and/or MDM4, and combinations comprising such compounds. | 2015-12-10 |
20150353564 | Processes for the Preparation of Chiral Beta Amino Acid Derivatives Using Asymmetric Hydrogenation Catalysts - This invention provides processes for the preparation of Sitagliptin and pharmaceutically acceptable salts thereof, said processes including enantioselective hydrogenation of a prochiral enamine using chiral ruthenium catalyst. | 2015-12-10 |
20150353565 | BTK INHIBITORS - The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I or pharmaceutically acceptable salts thereof. Formula I or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds in the treatment of Btk mediated disorders. | 2015-12-10 |
20150353566 | TRIAZINE COMPOUNDS AND A PROCESS FOR PREPARATION THEREOF - The present invention discloses triazine compounds of Formula II and a process to synthesize these compounds. Particularly, the invention provides one pot method to synthesize triazines nucleus, wherein the method comprises amination followed by using Leuckart reaction conditions of pyrrole/indole-2-carboxylates of Formula I to obtain corresponding triazine compounds of Formula II. | 2015-12-10 |
20150353567 | TRANSITION METAL-CATALYZED PROCESSES FOR THE PREPARATION OF N-ALLYL COMPOUNDS AND USE THEREOF - The present disclosure provides processes for the N-dealkylation of tertiary amines and the use of transition metal catalysts to prepare tertiary N-allyl amine derivatives and secondary amine derivatives thereof. The tertiary amines can be alkaloids and, more particularly, the tertiary amines can be opioids. In specific embodiments, the present disclosure provides methods for use in processes for the synthesis of naloxone and naltrexone from oripavine. | 2015-12-10 |
20150353568 | TRANSITION METAL-CATALYZED PROCESSES FOR THE PREPARATION OF N-ALLYL COMPOUNDS AND USE THEREOF - The present disclosure provides processes for the N-dealkylation of tertiary amines and the use of transition metal catalysts to prepare tertiary N-allyl amine derivatives and secondary amine derivatives thereof. The tertiary amines can be alkaloids and, more particularly, the tertiary amines can be opioids. In specific embodiments, the present disclosure provides methods for use in processes for the synthesis of naloxone and naltrexone from oripavine. | 2015-12-10 |
20150353569 | TRANSITION METAL-CATALYZED PROCESSES FOR THE PREPARATION OF N-ALLYL COMPOUNDS AND USE THEREOF - The present disclosure provides processes for the N-dealkylation of tertiary amines and the use of transition metal catalysts to prepare tertiary N-allyl amine derivatives and secondary amine derivatives thereof. The tertiary amines can be alkaloids and, more particularly, the tertiary amines can be opioids. In specific embodiments, the present disclosure provides methods for use in processes for the synthesis of naloxone and naltrexone from oripavine. | 2015-12-10 |
20150353570 | BTK INHIBITORS - The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds in the treatment of Btk mediated disorders. | 2015-12-10 |
20150353571 | 1,3-BENZOTHIAZINONE SULFOXIDE AND SULFONE COMPOUNDS - A compound, having the following formula: | 2015-12-10 |
20150353572 | 1,3-BENZOTHIAZINONE, SULFOXIDE, AND SULFONE COMPOUNDS WITH ELECTROPHILIC SUBSTITUENT - A compound, having the following formula: | 2015-12-10 |
20150353573 | GEM-DIFLUORINATED C-GLYCOSIDE COMPOUNDS AS ANTI-CANCER AGENTS - The present document describes a synthesis of a class of gem-difluorinated C-glycoside compounds derived from podophyllotoxin, which may be used, but not exclusively, in oncology for the treatment of cancer. More particularly, the podophyllotoxin gem-difluorinated C-glycoconjugated derivatives display improved conformational and chemical stability, and improved cytotoxicity exhibited against drug-resistant cancer cell lines. | 2015-12-10 |
20150353574 | METHOD FOR PRODUCING ANHYDROSUGAR ALCOHOL THROUGH CONTINUOUS DEHYDRATION REACTION OF HYDROGENATED SUGAR - The present invention relates to a method for producing an anhydrosugar alcohol and, more specifically, to a method for producing an anhydrosugar alcohol which, when the step of subjecting a hydrogenated sugar to a dehydration reaction in a reactor so as to convert same to an anhydrosugar alcohol is performed, allows the hydrogenated sugar to be continuously introduced into the reactor and the produced anhydrosugar alcohol to be continuously discharged out of the reactor while the dehydration reaction is carried out, also prevents a reaction mixture from circulating inside and outside the reactor while the dehydration reaction is carried out, and thereby can significantly improve production efficiency compared with a conventional process adopting a batch or semi-batch-type dehydration reaction and thus can be appropriately applied particularly to a large-scale anhydrosugar alcohol production process. | 2015-12-10 |
20150353575 | SEMICONDUCTING POLYMERS - The invention relates to novel polymers containing repeating units based on benzodithiophene or derivatives thereof, monomers and methods for their preparation, their use as semiconductors in organic electronic (OE) devices, especially in organic photovoltaic (OPV) devices, and to OE and OPV devices comprising these polymers. | 2015-12-10 |
20150353576 | (THIENO[2,3-b][1,5]BENZOXAZEPIN-4-YL)PIPERAZIN-1-YL COMPOUNDS AS DUAL ACTIVITY H1 INVERSE AGONISTS/5-HT2A ANTAGONISTS - A dual H1 inverse agonist/5-HT2A receptor antagonist of the formula: [Formula I], its uses, and methods for its preparation are described. | 2015-12-10 |
20150353577 | METHOD FOR PRODUCING (1S,4S,5S)-4-BROMO-6-OXABICYCLO[3.2.1]OCTAN-7-ONE - It is an object of the present invention to provide a method for efficiently producing (1S,4S,5S)-4-bromo-6-oxabicyclo[3.2.1]octan-7-one (1), which is important as an intermediate compound for the production of an FXa-inhibiting compound. A method for producing (1S,4S,5S)-4-bromo-6-oxabicyclo[3.2.1]octan-7-one (1), which comprises treating an (R)-α-phenylethylamine salt of (S)-3-cyclohexene-1-carboxylic acid with 1,3-dibromo-5,5-dimethylhydantoin or N-bromosuccinimide in a solvent. | 2015-12-10 |
20150353578 | HETEROCYCLIC COMPOUND AND USE THEREOF - Provided is a compound represented by the formula (I): | 2015-12-10 |
20150353579 | Triazine Derivatives - The present invention is directed to a new class of triazine derivatives as described by formula I below in which A, X, R | 2015-12-10 |
20150353580 | GOLD NANOPARTICLES AND METHODS OF MAKING AND USING GOLD NANOPARTICLES - Disclosed herein are embodiments of gold nanoparticles and methods of making and using the gold nanoparticles. The disclosed gold nanoparticles have core sizes and polydispersities controlled by the methods of making the gold nanoparticles. In some embodiments, the methods of making the gold nanoparticles can concern using flow reactors and reaction conditions controlled to make gold nanoparticles having a desired core size. The gold nanoparticles disclosed herein also comprise various ligands that can be used to facilitate the use of the gold nanoparticles in a variety of applications. | 2015-12-10 |
20150353581 | 1-HYDROXY-BENZOOXABOROLES AS ANTIPARASITIC AGENTS - Provided are compounds useful for controlling endoparasites both in animals and agriculture. Further provided are methods for controlling endoparasite infestations of an animal by administering an effective amount of a compound as described above, or a pharmaceutically acceptable salt thereof, to an animal, as well as formulations for controlling endoparasite infestations using the compounds described above or an acceptable salt thereof, and an acceptable carrier. The claimed compounds are described by the following Markush formula: A typical example for a compound according to above formula is: A typical example for a compound according to above formula is: | 2015-12-10 |
20150353582 | NORBORNENYLHYDROCARBYLENE DIHYDROCARBYLBORANES AND METHODS OF MAKING THE SAME - Embodiments of norbornenylhydrocarbylene dihydrocarbylboranes represented by the Formula (I), | 2015-12-10 |
20150353583 | REACTIVE COMPOUND - A reactive compound represented by the following formula (I): | 2015-12-10 |
20150353584 | SULFUR SCAVENGING MATERIALS - Materials which react with (“scavenge”) sulfur compounds, such as hydrogen sulfide and mercaptans, are useful for limiting sulfur-induced corrosion. Surface-modified particles incorporating a hexahydrotriazine moiety are disclosed and used as sulfur scavengers. These surface-modified particles are used a filter media in fixed filter systems and as additives to fluids including sulfur compounds. The hexahydrotriazine moiety can react with sulfur compounds in such a manner as to bind sulfur atoms to the surface-modified particles, thus allowing removal of the sulfur atoms from fluids such as crude oil, natural gas, hydrocarbon combustion exhaust gases, sulfur polluted air and water. The surface-modified particles may, in general, be sized to allow separation of the particles from the process fluid by sedimentation, size-exclusion filtration or the like. | 2015-12-10 |
20150353585 | ASYMMETRICAL SI RHODAMINE AND RHODOL SYNTHESIS - [Problem] To provide: a compound resulting from substituting with a silicon atom the oxygen atom at position 10 of a xanthene ring site of a rhodamine of which amino groups at position 3 and position 6 have an asymmetrical structure; a method for producing the compound; and a fluorescent probe that uses the compound. | 2015-12-10 |
20150353586 | PROCESS FOR ESTERIFYING SILICON-HALOGEN COMPOUNDS IN A COLUMN AND APPARATUS SUITABLE THEREFOR - What is described is a process for continuously esterifying halosilanes of the formula I with alcohols of the formula II to give silane esters of the formula III in a single column (1) | 2015-12-10 |
20150353587 | TRIORGANOBORANE-AMINO FUNCTIONALIZED NANOPARTICLES, COMPOSITIONS, AND METHODS - Surface-modified nanoparticles wherein each nanoparticle includes an inorganic core and surface modifying groups, wherein the surface modifying groups include at least one triorganoborane-amine complex having the structure —Z—NHR | 2015-12-10 |
20150353588 | GROUP 5 METAL OXO-ALKOXO COMPLEX, METHOD FOR PRODUCING SAME, AND METHOD FOR MANUFACTURING GROUP 5 METAL OXIDE FILM - A compound useful for the manufacture of a Group 5 metal oxide film is provided. The compound is a Group 5 metal oxo-alkoxo complex represented by the following formula (A), and after preparing a film-forming material solution containing the compound and an organic solvent, a Group 5 metal oxide film can be manufactured using the film-forming material solution: | 2015-12-10 |
20150353589 | FIRST ROW METAL-BASED CATALYSTS FOR HYDOSILYLATION - In various embodiments, the invention provides phosphine ligand supported first row metal catalysts with surprising and efficacious catalytic activity for hydrosilylation of pi-bonded substrates. Also provided are methods of using the catalysts of the invention to prepare hydrosilylated compounds. | 2015-12-10 |
20150353590 | METHODS AND COMPOSITIONS FOR TREATMENT OF CYANIDE AND HYDROGEN SULFIDE TOXICITY - A composition and method for treating excess cyanide and hydrogen sulfide comprising administering a cobinamide. Further a method for determining extent of binding by an agent to an extracellular matrix. | 2015-12-10 |
20150353591 | TITANOCENE-GOLD DERIVATIVES COMPRISING THIOLATO LIGANDS - Titanocene-gold compounds are provided that are useful for treating cancers. The disclose compounds generally have a formula given by: | 2015-12-10 |
20150353592 | FUNCTIONALIZATION AND PURIFICATION OF MOLECULES BY REVERSIBLE GROUP EXCHANGE - Embodiments of the present disclosure include methods and compositions for functionalizing molecules, such as oligonucleotides, with functional groups, including polyhistidine tags useful in affinity methods. Some embodiments include methods for modifying and purifying complex mixtures of molecules by exchange of functional tags. | 2015-12-10 |
20150353593 | Novel Process for the Preparation of (1-pyrazole-4-yl)-N-methylcarboxamide - The present invention relates to a novel process for the preparation of (1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl)-6-aminopurin-2-yl}pyrazole-4-yl)-N-methylcarboxamide. | 2015-12-10 |
20150353594 | Protecting Groups For "Z Nucleotide" And Methods Thereof - The present disclosure provides a unique methodology and protecting groups that enable synthesis of oligonucleotides having Z nucleotide in an easy, clean and site-specific fashion with high yield. In particular, the method causes little to no damage to oligonucleotide product and does not modify the Z nucleotide itself. The invention provides a viable protection strategy for efficient synthesis of long oligonucleotides with Z nucleotide incorporated therein. | 2015-12-10 |
20150353595 | COMPOUND, COMPOSITION AND METHOD FOR TREATING AND/OR AMEOLIORATING KIDNEY DISEASE - Disclosed herein are compositions and methods for the treatment or prophylaxis of a subject having or susceptible to a kidney disease. The method includes the step of administering to the subject a compound of formula (I) in a dose of about 1 to 10 mg/Kg to improve the glomerular filtration rate (GFR) of the subject for at least 4 folds as compared to the GFR of the subject before treatment, | 2015-12-10 |
20150353596 | 17-Substituted Steroid Compounds - The invention relates to the use of compounds to ameliorate or treat an condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3β-hydroxy-17β-aminoandrost-5-ene, 3β-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3α-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3β-hydroxy-16β-fluoro-17β-aminoandrost-5-ene, 1α,3β-dihydroxy-4α-fluoroandrost-5-ene-17-one, 1α,3β,17β-trihydroxy-4α-fluoroandrost-5-ene, 1β,3β-dihydroxy-6α-bromoandrost-5-ene, 1α-fluoro-3β,12α-dihydroxyandrost-5-ene-17-one, 1α-fluoro-3β,4α-dihydroxyandrost-5-ene and 4α-fluoro-3β,6α,17β-trihydroxyandrostane. | 2015-12-10 |
20150353597 | Intein Mediated Purification of Protein - The present invention includes methods, compositions, uses, and kits for purifying a protein of interest (POI) comprising contacting a first fusion protein comprising the POI fused to the C-terminus of an intein C-fragment with a second fusion protein comprising an intein N-fragment and a purification tag to form a complex between the first fusion protein and the second fusion protein, cleaving the POI from the intein C-fragment, wherein the protein is released from the complex; and isolating the POI; the present invention also includes fusion proteins and vector. | 2015-12-10 |
20150353598 | ENHANCED PURIFICATION OF ANTIBODIES AND ANTIBODY FRAGMENTS BY APATITE CHROMATOGRAPHY - Methods are disclosed for use of apatite chromatography, particularly without reliance upon phosphate gradients, for purification or separation of at least one intact non-aggregated antibody, or at least one immunoreactive antibody fragment, from an impure preparation. Integration of such methods into multi-step procedures with other fractionation methods are additionally disclosed. | 2015-12-10 |
20150353599 | METHOD FOR PURIFYING RECOMBINANT FSH - The present invention relates to a method for purifying a recombinant follicle stimulating hormone (FSH) or recombinant FSH variant. The method comprises the steps of subjecting a liquid containing a recombinant FSH or recombinant FSH variant to an anion exchange chromatography, to a hydrophobic interaction chromatography, and to a dye affinity chromatography, wherein these chromatographies may be performed in any order, and wherein the method neither comprises a weak anion exchange chromatography nor a reverse phase chromatography. The method of purification results in a high yield of recombinant FSH having a desired degree of purity. The obtained FSH is especially useful for the prophylaxis and treatment of disorders and medical indications where FSH preparations are considered as useful remedies. | 2015-12-10 |
20150353600 | Crystal Forms - The present invention features crystalline forms of Compound I. In one embodiment, a crystalline form of Compound I has characteristic peaks in the PXRD pattern as shown in any one of FIGS. | 2015-12-10 |
20150353601 | COMPOUNDS FOR ENZYME INHIBITION - One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention. | 2015-12-10 |
20150353602 | METHODS FOR PREVENTION AND TREATMENT OF ACUTE RENAL INJURY - The disclosure relates to a method for protecting a kidney from renal injury. For example, acute renal injury may be associated with decreased or blocked blood flow in the subject's kidney or exposure to a nephrotoxic agent, such as a radiocontrast dye. The methods include administering to the subject an effective amount of an aromatic-cationic peptide to a subject in need thereof. | 2015-12-10 |
20150353603 | ENDOMETRIOSIS CELL TARGETING PEPTIDE AND USES THEREOF - Provided herein are compositions and methods for selectively targeting an endometriosis cell. | 2015-12-10 |
20150353604 | COMPOSITIONS FOR LABELING NERVES AND METHODS OF USE - The present invention provides methods for guiding preservation of neurons or nerves during surgery by administering a fluorescently-labeled peptide that associates with (e.g., specifically binds to) the neurons or nerves. The invention further provides targeting molecules of fluorescently-labeled peptides or aptamers that associate with (e.g., specifically bind to) neurons or nerves and for compositions thereof. | 2015-12-10 |
20150353605 | SHORT BIO-ACTIVE PEPTIDES FOR PROMOTING WOUND HEALING - Peptides having four to six amino acid residues are disclosed that possess biological activity. These peptides constitute short fragments of the peptide HB-107 (MPKEKVFLKIEKMGRNIRN), which itself is a fragment of the antimicrobial protein cecropin B, and exhibit cell stimulatory and migratory properties. The inventive peptides comprise four to six contiguous amino acid residues located between position 11 and 16 of HB107 (MPKEKVFLKIEKMGRNIRN), namely EKMGRN. The disclosed peptides comprise a useful agent for the medical treatment of injury to the skin, such as from diabetic ulcers. The peptides also are effective in preventing and reversing skin surface damage resulting from various environmental insults Importantly, the therapeutic effects of the peptides manifest at concentrations equal to or greater than those of peptide HB-107, and thus represent a less expensive, more versatile means for developing effective therapies. Methods for the production and use of these peptides are also disclosed. | 2015-12-10 |
20150353606 | PEPTIDOMIMETIC COMPOUNDS - The present invention relates to inhibitors of protein-protein interactions (PPI). Specifically, the present invention relates to a structural informatics approach to designing peptidomimetic macrocycles containing an amino acid “warhead” for ligand-directed covalent modification of cysteine and lysine-containing proteins for the treatment of diseases such as cancer. Further included is the targeting of components of the BCL2 signaling pathway, specifically BCL2-A1 and MCL-1. | 2015-12-10 |
20150353607 | Glycopeptide Compound Or Pharmaceutical Salt Thereof And Method For Preparing Same, And Pharmaceutical Compositions And Applications Thereof - The present invention provides a glycopeptide compound or pharmaceutically acceptable salt thereof as shown in Formula (I) or (II), and a method for preparing same, and pharmaceutical compositions and applications thereof, wherein the definition of R | 2015-12-10 |
20150353608 | ANTIBODY-BINDING PEPTIDE - The invention relates to polypeptides consisting of amino acid sequences represented by the following formulas 1 to 4, which have binding activity to an Fc region of immunoglobulin G and can be favorably used in detecting, purifying, immobilizing or removing an antibody, immunoglobulin G or a protein containing an Fc region of immunoglobulin G, | 2015-12-10 |
20150353609 | MONOMERIC AND BRIGHT INFRARED FLUORESCENT PROTEINS - The invention described herein features variants related to infrared fluorescent proteins, in particular to mutants of a phytochrome from the bacterium | 2015-12-10 |
20150353610 | NOVEL RECOMBINANT OUTER MEMBRANE PROTEINS FROM BRACHYSPIRA HYODYSENTERIAE AND USES THEREOF - The present invention relates generally to the field of diarrhoeal diseases caused by intestinal spirochaetes. Specifically, the invention relates to the prevention and/or treatment of infections with | 2015-12-10 |
20150353611 | IMPROVED NISIN PRODUCTION PROCESS - The present invention relates to fermentation processes. The objective of the invention was to provide methods for producing nisin containing ferments and formulating such ferments into preservatives. It was in particular an object of the present invention to provide improved processes for producing nisin containing ferments by simple and efficient (batch) culturing and allowing for simple down-stream processing either into a liquid, semi-liquid or a dry powder product, having sufficient nisin content and stability, good handling properties and satisfactory organoleptic properties. Such processes are provided, as well as the products that can be obtained with it and their use. | 2015-12-10 |
20150353612 | NUCLEIC ACIDS ENCODING PEPTIDES FOR TREATING WOUNDS, ANTI-ANGIOGENIC COMPOUNDS AND USES THEREOF - The present disclosure relates to protein and peptide chemistry. More particularly, it relates to compounds, compositions and uses thereof for promoting and inhibiting angiogenesis. The peptides of the present disclosure include peptides comprising SEQ ID NOs: 1-4 which promote angiogenesis and cell proliferation. Further, the anti-angiogenic compounds of the present disclosure include antisense oligonucleotides that hybridize or are complementary to the polynucleotides of SEQ ID NOs: 5-16, and the like. | 2015-12-10 |
20150353613 | STABILIZED STAT3 DECOY OLIGONUCLEOTIDES AND USES THEREFORE - The present invention is based, at least in part, on novel, unimolecular STAT3 oligonucleotide decoys exhibiting increased in vivo stability as compared to previously known decoys which are effective in inhibiting STAT3 when administered systemically. The invention is also based on pharmaceutical compositions comprising these unimolecular decoys, and methods for using these decoys in the treatment of cancer. | 2015-12-10 |
20150353614 | Synthetic Transcription Factor and Uses Thereof - The present invention provides for a synthetic transcription factor (TF) comprising a first peptide capable of binding a target ligand, a second peptide capable of binding a target DNA, and a peptide linker linking the first and second peptides. The present invention also provide for a system for modulating the mutagenesis frequency of a host cell. The host cell has a mutator rate (R) which is inversely proportional to a phenotypic trait (P). | 2015-12-10 |
20150353615 | POSITIVE MODULATOR OF BONE MORPHOGENIC PROTEIN-2 - Compounds of the present invention of formula I and formula II are disclosed in the specification and wherein the compounds are modulators of Bone Morphogenic Protein activity. Compounds are synthetic peptides having a non-growth factor heparin binding region, a linker, and sequences that bind specifically to a receptor for Bone Morphogenic Protein. Uses of compounds of the present invention in the treatment of bone lesions, degenerative joint disease and to enhance bone formation are disclosed. | 2015-12-10 |
20150353616 | PEPTIDE - There is provided a peptide which is capable of binding to an MHC molecule in vitro and being presented to a T cell without antigen processing (i.e. an apitope) which peptide comprises a portion of the region 40-60 of myelin oligodendrocyte glycoprotein (MOG). In particular there is provided an apitope which is selected from the following myelin oligodendrocyte glycoprotein peptides: MOG 41-55, 43-57, 44-58 and 45-59. There is also provided the use of such a peptide in a pharmaceutical composition and a method to treat and/or prevent a disease using such a peptide. | 2015-12-10 |
20150353617 | ANTI-ANGIOGENIC VEGF-AX ISOFORM - A VEGF-Ax polypeptide, as well as a smaller Ax poly-peptide, both having anti-angiogenic activity that can be used for treating or preventing angiogenesis are described. An antibody specific to the Ax region of a VEGF-Ax polypeptide, as well as an antibody specific to the C-terminus region of a VEGF-A polypeptide that is not capable of binding to VEGF-Ax, and methods of using these antibodies, are also described. | 2015-12-10 |